BCL2L1 and meningioma: In support of this result, the suppression of Bcl-xL expression by siRNA and the inhibition of Bcl-xL by A-1331852, a Bcl-xL-specific inhibitor, sensitized malignant meningioma cells to the combination of gemcitabine and radiation (Supplementary Figures S10B, C and S11).